The Value of Medicines: A Crucial but Vague Concept-Reference-Cited by-同舟云学术

The Value of Medicines: A Crucial but Vague Concept

Published:2016-07-21 Issue:12 Volume:34 Page:1227-1239
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Antoñanzas Fernando^ORCID,Terkola Robert,Postma Maarten

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-016-0434-8.pdf

Reference80 articles.

1. Vogler S, Habl C, Bogut M, Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011;52(2):183–97.

2. Levaggi R, Pertile P. Drug prices and incentives to innovation by the pharmaceutical industry. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015. p. 389–401.

3. McGuire A, Raikou M, Kanavos P. Pricing pharmaceuticals: value based pricing in what sense? 2008. http://apps.who.int/medicinedocs/documents/s20973en/s20973en.pdf . Accessed 7 May 2015.

4. Hughes DA. Value-based pricing: incentive for innovation or zero net benefit? Pharmacoeconomics. 2011;29(9):731–5.

5. Miller DW. Value-based pricing examples of healthcare system reforms from the UK and US and implications for industry. Pharm Med. 2012;26(4):217–22.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding medicine access strategies for innovative medicines registered in South Africa;2024-06-19

2. New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices;Current Oncology;2024-04-28

3. The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue;Journal of Cancer Policy;2023-12

4. Implementing a Managed Entry Agreement Framework in Cyprus;Expert Review of Pharmacoeconomics & Outcomes Research;2023-07-23

5. Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review;Economies;2023-01-12